Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.

Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.

PMID:
30042063
2.

Predicting early death in older adults with cancer.

Boulahssass R, Gonfrier S, Ferrero JM, Sanchez M, Mari V, Moranne O, Rambaud C, Auben F, Hannoun Levi JM, Bereder JM, Bereder I, Baque P, Turpin JM, Frin AC, Ouvrier D, Borchiellini D, Largillier R, Sacco G, Delotte J, Arlaud C, Benchimol D, Durand M, Evesque L, Mahamat A, Poissonnet G, Mouroux J, Barriere J, Benizri E, Piche T, Guigay J, Francois E, Guerin O.

Eur J Cancer. 2018 Sep;100:65-74. doi: 10.1016/j.ejca.2018.04.013. Epub 2018 Jun 29.

PMID:
30014882
3.

Things Are Changing so Fast: Integrative Technology for Preserving Cognitive Health and Community History.

Croff RL, Witter Iv P, Walker ML, Francois E, Quinn C, Riley TC, Sharma NF, Kaye JA.

Gerontologist. 2018 Jun 29. doi: 10.1093/geront/gny069. [Epub ahead of print]

PMID:
29961887
4.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators.

Eur J Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.

5.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

Aparicio T, Bouché O, Francois E, Retornaz F, Barbier E, Taieb J, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Bedenne L, Paillaud E; for PRODIGE 20 investigators.

Eur J Cancer. 2018 Jul;97:16-24. doi: 10.1016/j.ejca.2018.03.030. Epub 2018 May 16.

PMID:
29777975
6.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators.

Ann Oncol. 2018 Apr 30. doi: 10.1093/annonc/mdx808. [Epub ahead of print] No abstract available.

PMID:
29718089
7.

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy.

Yu Q, Morales M, Li N, Fritz AG, Ruobing R, Blaeser A, Francois E, Lu QL, Nagaraju K, Spurney CF.

Skelet Muscle. 2018 Apr 6;8(1):13. doi: 10.1186/s13395-018-0158-x.

8.

Jaundice in a pregnant woman.

Ibrahimi S, Mroué AA, Francois E, Jagodzinski R.

Acta Gastroenterol Belg. 2017 Jul-Sep;80(3):422-424.

PMID:
29560675
9.

Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.

Rouyer M, François E, Cunha AS, Monnereau A, Noize P, Robinson P, Droz-Perroteau C, Le Monies de Sagazan A, Jové J, Lassalle R, Moore N, Fourrier-Réglat A, Smith D; EREBUS Study Group.

Clin Colorectal Cancer. 2018 Jun;17(2):129-139. doi: 10.1016/j.clcc.2018.01.007. Epub 2018 Jan 31.

PMID:
29523416
10.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J; PRODIGE 9 Investigators.

J Clin Oncol. 2018 Mar 1;36(7):674-681. doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.

PMID:
29346040
11.

Is Minimally Invasive Transforaminal Interbody Fusion Superior to Traditional Open Technique?

Wanderman NR, Francois EL, Nassr A, Sebastian AS.

Clin Spine Surg. 2018 May;31(4):139-142. doi: 10.1097/BSD.0000000000000596. No abstract available.

PMID:
29135609
12.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators.

Ann Oncol. 2018 Jan 1;29(1):133-138. doi: 10.1093/annonc/mdx529.

13.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.

Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Gourgou-Bourgade S, Juzyna B, Conroy T, Gérard J.

Ann Oncol. 2017 Oct 1;28(10):2436-2442. doi: 10.1093/annonc/mdx351.

PMID:
28961836
14.

In reply.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Philippe Metges J, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Apr;44(2):161. doi: 10.1053/j.seminoncol.2017.08.002. Epub 2017 Aug 4. No abstract available.

PMID:
28923216
15.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.

16.

Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.

Evesque L, Benezery K, Follana P, Tuan Falk A, Doyen J, Reure J, Cavaglione G, François E.

Dis Colon Rectum. 2017 Aug;60(8):785-791. doi: 10.1097/DCR.0000000000000827.

PMID:
28682963
17.

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP).

Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouché O.

Dig Liver Dis. 2017 Aug;49(8):831-840. doi: 10.1016/j.dld.2017.05.011. Epub 2017 May 23. Review.

PMID:
28610905
18.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J.

Eur J Cancer. 2017 Jul;79:15-22. doi: 10.1016/j.ejca.2017.03.036. Epub 2017 Apr 26.

PMID:
28456090
19.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. Epub 2017 Feb 11.

PMID:
28395758
20.

Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.

Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L.

Ther Drug Monit. 2017 Jun;39(3):290-296. doi: 10.1097/FTD.0000000000000399.

PMID:
28346313
21.

Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.

Frin AC, Evesque L, Gal J, Benezery K, François E, Gugenheim J, Benizri E, Château Y, Marcié S, Doyen J, Gérard JP.

Eur J Cancer. 2017 Feb;72:124-136. doi: 10.1016/j.ejca.2016.11.007. Epub 2016 Dec 24.

PMID:
28027515
22.

Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy.

Kinj R, Bondiau PY, François E, Gérard JP, Naghavi AO, Leysalle A, Chamorey E, Evesque L, Padovani B, Ianessi A, Benezery K, Doyen J.

Clin Colorectal Cancer. 2017 Sep;16(3):e211-e220. doi: 10.1016/j.clcc.2016.08.003. Epub 2016 Aug 31.

PMID:
27670890
23.

The Gustilo-Anderson classification system as predictor of nonunion and infection in open tibia fractures.

Thakore RV, Francois EL, Nwosu SK, Attum B, Whiting PS, Siuta MA, Benvenuti MA, Smith AK, Shen MS, Mousavi I, Obremskey WT, Sethi MK.

Eur J Trauma Emerg Surg. 2017 Oct;43(5):651-656. doi: 10.1007/s00068-016-0725-y. Epub 2016 Sep 22.

PMID:
27658943
24.

Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.

Reure J, Follana P, Gal J, Evesque L, Cavaglione G, Saint A, François E.

Oncology. 2016;90(5):261-6. doi: 10.1159/000444854. Epub 2016 Apr 21.

PMID:
27097162
25.

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.

Kotecki N, Hiret S, Etienne PL, Penel N, Tresch E, François E, Galais MP, Ben Abdelghani M, Michel P, Dahan L, Ghiringelli F, Bedenne L, Samalin E, Piessen G, Bennouna J, Peugniez C, El Hajbi F, Clisant S, Kramar A, Mariette C, Adenis A.

Oncology. 2016;90(2):88-96. doi: 10.1159/000442947. Epub 2016 Jan 20.

PMID:
26784946
26.

PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.

Aparicio T, Francois E, Cristol-Dalstein L, Carola E, Maillard E, Paillaud E, Retornaz F, Faroux R, André T, Bedenne L, Seitz JF.

Dig Liver Dis. 2016 Feb;48(2):206-7. doi: 10.1016/j.dld.2015.11.023. Epub 2015 Dec 2. No abstract available.

PMID:
26748426
27.

The rise and fall of the craniocervical junction relative to the hard palate: a lifetime story.

Mallory GW, Arutyunyan G, Murphy ME, Van Abel KM, Francois E, Wetjen NM, Fogelson JL, O'Brien EK, Clarke MJ, Eckel LJ, Van Gompel JJ.

J Neurosurg Spine. 2016 Apr;24(4):521-6. doi: 10.3171/2015.6.SPINE141250. Epub 2015 Dec 11.

PMID:
26654341
28.

Surgical site infection in orthopedic trauma: A case-control study evaluating risk factors and cost.

Thakore RV, Greenberg SE, Shi H, Foxx AM, Francois EL, Prablek MA, Nwosu SK, Archer KR, Ehrenfeld JM, Obremskey WT, Sethi MK.

J Clin Orthop Trauma. 2015 Dec;6(4):220-6. doi: 10.1016/j.jcot.2015.04.004. Epub 2015 Jun 18.

29.

[Management and clinical outcome in patients over 80 years with rectal cancer treated between 2006 and 2008 in Southern France (PACA region)].

Moureau-Zabotto L, Gal J, Resbeut M, Mineur L, Teissier É, Hébuterne X, Muyldermans P, Francois É, Chamorey E, Gérard JP.

Cancer Radiother. 2015 Dec;19(8):725-32. doi: 10.1016/j.canrad.2015.05.029. Epub 2015 Nov 11. French.

PMID:
26548601
30.

Increased reintervention in radial-cephalic arteriovenous fistulas with anastomotic angles of less than 30 degrees.

Sadaghianloo N, Jean-Baptiste E, Rajhi K, François E, Declemy S, Dardik A, Hassen-Khodja R.

J Vasc Surg. 2015 Dec;62(6):1583-9. doi: 10.1016/j.jvs.2015.07.074. Epub 2015 Sep 10.

31.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E, André T, Seitz JF, Montérymard C, Arsene D, Volet J, Abakar-Mahamat A, Lecomte T, Guerin-Meyer V, Legoux JL, Deplanque G, Guillet P, Ciccolini J, Lepage C, Dahan L.

PLoS One. 2015 Aug 26;10(8):e0135907. doi: 10.1371/journal.pone.0135907. eCollection 2015.

32.

[Peri-operative treatments for rectal cancer].

Gérard JP, Doyen J, Bénézery K, Borens B, Hannoun-Levi JM, François É.

Rev Prat. 2015 Jun;65(6):784-8. French.

PMID:
26298900
33.

Dorsal Root Ganglion (DRG) Stimulation in the Treatment of Phantom Limb Pain (PLP).

Eldabe S, Burger K, Moser H, Klase D, Schu S, Wahlstedt A, Vanderick B, Francois E, Kramer J, Subbaroyan J.

Neuromodulation. 2015 Oct;18(7):610-6; discussion 616-7. doi: 10.1111/ner.12338. Epub 2015 Aug 13.

PMID:
26268453
34.

Non Digestible Oligosaccharides Modulate the Gut Microbiota to Control the Development of Leukemia and Associated Cachexia in Mice.

Bindels LB, Neyrinck AM, Salazar N, Taminiau B, Druart C, Muccioli GG, François E, Blecker C, Richel A, Daube G, Mahillon J, de los Reyes-Gavilán CG, Cani PD, Delzenne NM.

PLoS One. 2015 Jun 22;10(6):e0131009. doi: 10.1371/journal.pone.0131009. eCollection 2015.

35.

Open distal tibial shaft fractures: a retrospective comparison of medial plate versus nail fixation.

Avilucea FR, Sathiyakumar V, Greenberg SE, Ghiam M, Thakore RV, Francois E, Benvenuti MA, Siuta M, Smith AK, Ehrenfeld JM, Evans JM, Obremskey WT, Sethi MK.

Eur J Trauma Emerg Surg. 2016 Feb;42(1):101-6. doi: 10.1007/s00068-015-0519-7. Epub 2015 Mar 25.

PMID:
26038037
36.

Bevacizumab: A dose review.

Falk AT, Barrière J, François E, Follana P.

Crit Rev Oncol Hematol. 2015 Jun;94(3):311-22. doi: 10.1016/j.critrevonc.2015.01.012. Epub 2015 Feb 7. Review.

PMID:
25703583
37.

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

Aparicio T, Linot B, Le Malicot K, Bouché O, Boige V, François E, Ghiringhelli F, Legoux JL, Ben Abdelghani M, Phelip JM, Faroux R, Dahan L, Taieb J, Bedenne L.

Dig Liver Dis. 2015 Apr;47(4):271-2. doi: 10.1016/j.dld.2015.01.146. Epub 2015 Jan 20. No abstract available.

PMID:
25677925
38.

Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud - nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients.

Gerard JP, Frin AC, Doyen J, Zhou FX, Gal J, Romestaing P, Barbet N, Coquard R, Chapet O, François E, Marcié S, Benezery K.

Acta Oncol. 2015 Apr;54(4):545-51. doi: 10.3109/0284186X.2014.975840. Epub 2014 Nov 12. No abstract available.

PMID:
25389568
39.

Interstitial high-dose rate brachytherapy as boost for anal canal cancer.

Falk AT, Claren A, Benezery K, François E, Gautier M, Gerard JP, Hannoun-Levi JM.

Radiat Oncol. 2014 Nov 6;9:240. doi: 10.1186/s13014-014-0240-4.

40.

[Vaginal metastasis revealing an adenocarcinoma of the transverse colon].

Quaranta D, Delotte J, Bongain A, François E, Bereder JM, Bernard JL.

Gynecol Obstet Fertil. 2014 Sep;42(9):622-5. doi: 10.1016/j.gyobfe.2014.07.019. Epub 2014 Aug 19. French.

PMID:
25153435
41.

Aims of combined modality therapy in rectal cancer (M0).

Gerard JP, Benezery K, Doyen J, Francois E.

Recent Results Cancer Res. 2014;203:153-69. doi: 10.1007/978-3-319-08060-4_11. Review.

PMID:
25103004
43.

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R, Terrebonne E, De La Fouchardière C, Manfredi S, Solub D, Lécaille C, Thirot Bidault A, Carbonnel F, Taieb J.

Ann Surg Oncol. 2015 Jan;22(1):295-301. doi: 10.1245/s10434-014-3898-9. Epub 2014 Jul 19.

PMID:
25037971
44.

Recommendations for bowel obstruction with peritoneal carcinomatosis.

Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, Copel L, Durand A, Francois E, Gabolde M, Mariani P, Rebischung C, Servois V, Terrebonne E, Arvieux C; French Society for Palliative Care; French Society for Digestive Surgery; French Society for Gastroenterology; French Association for Supportive Care in Oncology; French Society for Digestive Cancer.

J Pain Symptom Manage. 2014 Jul;48(1):75-91. doi: 10.1016/j.jpainsymman.2013.08.022. Epub 2014 May 4. Review.

PMID:
24798105
45.

Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.

Saada E, Saint Paul MC, Gugenheim J, Follana P, François E.

Oncol Res Treat. 2014;37(3):124-6. doi: 10.1159/000360208. Epub 2014 Feb 21.

PMID:
24685916
46.

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

Lombard-Bohas C, Cariou B, Vergès B, Coriat R, N'guyen T, François E, Hammel P, Niccoli P, Hentic O.

Bull Cancer. 2014 Feb;101(2):175-83. doi: 10.1684/bdc.2014.1887. Review. French.

PMID:
24557872
47.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group.

Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

PMID:
24556041
48.

Results of age-dependent anal canal cancer treatment: a single centre retrospective study.

Claren A, Doyen J, Falk AT, Benezery K, Follana P, Frin AC, Hannoun-Lévi JM, Cavaglione G, Mari V, Gérard JP, François E.

Dig Liver Dis. 2014 May;46(5):460-4. doi: 10.1016/j.dld.2014.01.004. Epub 2014 Feb 17.

PMID:
24555918
49.

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

François E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Seitz JF, Conroy T, Juzyna B, Gerard JP.

Radiother Oncol. 2014 Jan;110(1):144-9. doi: 10.1016/j.radonc.2013.10.019. Epub 2014 Jan 10.

PMID:
24418359
50.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T.

Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9.

Supplemental Content

Loading ...
Support Center